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Introduction
Diphtheria toxin-like ADP-ribosyl transferases (ARTDs), better known as poly(ADP-ribose) polymerases (PARPs), use nicotinamide adenine dinucleotide (NAD þ ) as co-substrate to transfer ADP-ribose to their target proteins [1, 2] . PARPs catalyze the formation of linear or branched poly(ADP-ribose) chains, dynamic structures that are recognized by a number of reader domains and broken down by poly(ADP-ribose) glycohydrolases [3] . A large subset of the PARP family catalyzes mono-ADP-ribosylation but not chain elongation [1, 4, 5] (Fig. 1A) . Recently, functional information has been accumulating on these mono-ADP-ribosyltransferases (mARTDs) [6, 7] . Most of them combine an ADP-ribosyltransferase domain with ADP-ribose binding macro domains or WWE-domains, CCCH-type zinc finger domains, and other proteineprotein interaction modules. The macro domain containing ARTD7/PARP15, ARTD8/PARP14 and ARTD9/PARP9 are overexpressed in diffuse large B-cell lymphoma, and ARTD8 is implicated in the regulation of gene transcription [8e10] . ARTD10 is a component in the NF-kB signaling pathway by directly modifying NEMO [11] . Specific mono-ADP-ribose reader and eraser domains are also beginning to be recognized [3, 12] .
Numerous drug discovery programs have been dedicated to PARP inhibitors [13, 14] . The predominant therapeutic area is cancer, where inhibition of ARTD1 is beneficial, in particular in combination with DNA damage repair deficiencies [15, 16] . The majority of current PARP inhibitors are nicotinamide mimics that display broad inhibition of PARPs in vitro [17, 18] . Less attention has been put on identification of selective inhibitors of mARTDs. Recently Venkannagri et al. screened a library consisting of 502 natural products and identified several ARTD10/PARP10 inhibitors with varying potencies [19] . The potential of these inhibitors remains to be established since the compounds were not characterized by a full doseresponse analysis and profiling against other members of the ARTD/PARP enzyme family. We have previously identified structural features in both enzymes and small molecule inhibitors that might facilitate the development of selective PARP inhibitors [17] . Based on that analysis we have developed and presented virtual screening procedures to identify compounds 1 and 2 as starting points for development of potent and selective mARTD inhibitors (Table 1) [20] . Here we describe a medicinal chemistry program with the aim to develop potent inhibitors of ARTD7, -8, and -10.
Results and discussion
Compounds 1 and 2 (Table 1) were discovered in a virtual screen and verified as binders to ARTD7 and -8 by isothermal titration calorimetry and x-ray crystallography [20] . We have now developed robust enzymatic assays for these two enzymes as well as ARTD10 and could establish that both compounds indeed inhibit the enzymatic activity of all three enzymes (Table 1 ). We found that 1 and 2 are more potent as ARTD10 inhibitors, with IC 50 values of 1.3 mM and 10.6 mM respectively. Based on these promising results a set of analogues of 1 and 2 ( Table 1 ) was designed to explore the structure-activity relationship (SAR) for inhibition of ARTD7, -8 and -10 in relation to ARTD1. The compounds can readily be synthesized from commercially available building blocks as outlined in Scheme 1. Aminobenzamides are reacted with carboxylic anhydrides or carboxylic acids to give target compounds, and for a subset the resulting carboxylic acid is further functionalized to esters or amides. Fig. 1B illustrates the moieties explored within the SAR series and Table 1 presents enzymatic inhibition data against ARTD7, -8 and -10 as well as ARTD1.
Previous data and crystal structures (e.g. Ref. [17] ) indicated that the benzamide in position I was likely to be crucial for enzyme inhibition, and many known PARP inhibitors contains a benzamide functionality that mimics the nicotinamide in NAD þ [21] . The amide forms a bifurcated hydrogen bond interaction to a conserved backbone glycine in the active site of the enzymes. Comparison of existing crystal structures indicated that the volume that harbors the amide is similar between ARTD1 and the mARTDs, but there are significant local differences in amino acid composition. To address selectivity between ARTD1 and the mARTDs, we decided to investigate whether the amide position I (Fig. 1B) is equally important for inhibition of ARTD7, -8 and -10. Moving the amide to position 4 relative to the anilide (3) abolished inhibition, which indicates that the amide in this position is crucial for inhibition of both mono-and poly-ADP-ribosylation ( Table 1) . Functionalization of the amide itself influenced the solubility dramatically, and compounds 4e6 could not be analyzed in the enzymatic assay. Subsequently, additional substituents were introduced on benzene ring II (Fig. 1B, 7 , 8, and 9) and also these modifications abolished inhibition, indicating that the binding site accommodating the benzene ring is restricted in size. The role of the double bond in position III (Fig. 1B ) was explored by various modifications including saturation (10), addition of methyl or methoxy groups (11, 12, 13 and 14) , and ring formations (15, 16, and 17) . The chiral compounds 13, 15, and 26 were prepared and evaluated as racemates. Most of these compounds retained activity with profiles similar to those for 1 and 2, with mM potency against ARTD10, ARTD7, and ARTD1. However, ARTD8 appears to be more resistant to inhibition. Saturation was well tolerated (10) and some alterations, such as the specific methylation in 12, seem favorable for ARTD7 inhibition. Certain ring formations with retained cis configuration (15, 16, and 17) were relatively well tolerated. The carbon chain in position III (Fig. 1B) was then extended (18) and, compared to the shorter chain in 10, this slightly decreased the inhibition of ARTD7 and -10. The importance of the carboxylic acid (position IV, Fig. 1B ) was explored by modifying it into alkylated amides (19, 20, 21 and 22) , a methyl ester (e.g., 23) or ketones (24, 25 and 26) . To our surprise the methyl amide, 19, with cis configuration could not be isolated using the standard synthetic procedure. Instead we attempted a solid-phase synthesis strategy according to the 9-fluorenylmethoxycarbonyl (Fmoc) protocol [22] as outlined in Scheme 2. Using this method, 19 was successfully synthesized. While this synthesis consists of more steps its overall ease makes it suitable for parallel synthesis of this class of compounds. After evaluation of enzyme inhibition it became clear that the methyl ester and methyl amides all are potent inhibitors of mARTDs ( Table 1 ). The methyl ester (23) is the most potent compound but it is undiscriminating with respect to the four enzymes, with IC 50 values around 1 mM for ARTD7, -8, and -10, and 4.4 mM for ARTD1. In addition, the methyl ester is less attractive due to potential ester hydrolysis in cellular systems, a reaction that would produce parent compound 2. The methyl amides 19 and 20 proved to be bioisosteric and the cis configuration in 19 provides selectivity for ARTD10 over ARTD7 and 8, and to some extent over ARTD1. Larger amides in compounds with cis configuration (21 and 22) reduced potency against ARTD10, -8, and -7 and improved inhibition of ARTD1. The methyl ester 23 and the methyl amides 19 and 20 are as potent as the parent compounds 1 and 2; the presumed anionic charge of the carboxylic acid is not crucial for inhibition; and the additional hydrogen bond donor present in the amides has limited effect on inhibition. The ketone-containing compounds 24, 25, and 26 inhibited ARTD10 and ARTD1 in particular. In general it is clear that small structural modifications can be exploited to affect both potency and selectivity. The compounds presented here are attractive starting points for a medicinal chemistry program targeting mARTDs due to their lead like properties [23, 24] . These generally include a smaller size, lower hydrophobicity, and higher water solubility compared to phase IeIII ARTD/PARP inhibitors such as Olaparib (Supplementary  Table S10 ). All presented compounds that display potencies below 10 mM have molecular weights below 350, LogP values well below 4, and the numbers of hydrogen bond donors and acceptors are below 4 and 8, respectively. This together with synthetic feasibility and ease of functionalization strongly favors this class of compound for further development into selective mARTD inhibitors.
Conclusions
We have developed and investigated a set of analogous compounds and their inhibition of the catalytic activities of ARTD7, -8 and -10 as well as the dominant clinical target ARTD1. Several new compounds showed an improved potency for one or more ARTDs compared to compounds 1 and 2. To conclude the SAR analysis, placing the anilide moiety in para-position on the benzamide, or alkylating the benzamide, both proved detrimental to enzyme inhibition, suggesting that the interactions between the compounds and the nicotinamide pocket is similar and crucial in both mono-and poly-ARTDs. The carboxylic acid present in the original hit molecules is not crucial the inhibition. The methyl ester 23 is best suited for targeted inhibition of ARTD7, -8 and -10 while the methyl amide 19 is selective for ARTD10. These are the first reported fully characterized compounds that inhibit the activity of mARTD enzymes and we anticipate that their potencies and selectivity over ARTD1 can be improved. Compound 19 in particular shows promise as a selective ARDT10 inhibitor. The compound class is attractive in terms of both physicochemical properties and synthetic feasibility, which encourages optimization of compound metabolic stability and ARTD isoform selectivity.
Experimental section

Chemistry
The majority of compounds included in this study were synthesized starting from aminobenzamides and anhydrides (Scheme 1). These substrates were dissolved in THF and left to stir at room temperature overnight. The precipitates were then collected and dried in vacuo to give the desired products. Esterification could then be accomplished by refluxing in methanol with catalytic H 2 SO 4 , followed by purification by column chromatography on silica gel. Unless otherwise noted, all compounds had a purity of >95% determined from HPLC. Detailed synthetic procedures and compound characterization are presented in the Supplementary Data.
Compound 19 was synthesized by solid-phase chemistry according to the standard Fmoc protocol [22] . Fmoc deprotection of the RINK-amide resin was achieved through a two-cycles treatment 
Recombinant protein production and purification
The cDNA fragments encoding human ARTD1 (full length), ARTD7 (amino acids 459e656, encoding the catalytic domain), ARTD8 (amino acids 1611e1801, encoding the catalytic and WWE domains), and ARTD10 (full length) were inserted into pNIC-Bsa4 [25] . Protein expression in Escherichia coli strains BL21(DE3) pRARE, and purification using immobilized metal affinity chromatography followed by size exclusion chromatography (SEC) were carried out as previously described [17] with minor modifications.
Enzymatic assay
Enzyme automodification was measured essentially as previously described [26] . Briefly, 50-ml aliquots of hexahistidine-tagged enzymes (50e200 nM in 50 mM HEPES pH 7.5, 100 mM NaCl, 4 mM MgCl 2 , 0.2 mM TCEP) were immobilized on Ni 2þ -chelating plates (5-PRIME). Compounds were added from stock solutions in DMSO followed by 15 min incubation at 20 C. The final concentration of DMSO was 1% in all reactions. ADP-ribosyltransferase reactions were started by addition of NAD þ (2% biotineNAD þ ; Trevigen) to a concentration below the respective K M at 20 C. After stopping the reactions with 7 M guanidine hydrochloride and washing, assay plates were incubated with streptavidin-conjugated horseradish peroxidase (0.5 mg/ml; Jackson Immunoresearch) and chemiluminescence detection was carried out using SuperSignal West Pico (Thermo Fisher Scientific) in a CLARIOstar microplate reader (BMG Labtech). Dose-response experiments were carried out at ten different concentrations in two technical replicate series and 1e4 biological replicates, and were evaluated by three-parameter regression analysis and curve fitting with no further constraints using GraphPad Prism. All reported IC 50 values are best-fit values for representative experiments and are given in mM and the -log IC 50 in molar concentration.
